The link between VLA-4 and JC virus reactivation (Q37965603)

26 August 2017

title

The link between VLA-4 and JC virus reactivation (English)

1 reference

26 August 2017

author name string

Maria Chiara G Monaco

series ordinal

1

1 reference

26 August 2017

Eugene O Major

series ordinal

2

1 reference

26 August 2017

publication date

1 January 2012

1 reference

Expert Review of Clinical Immunology

26 August 2017

published in

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

63-72

1 reference

Integrin ligands at a glance

26 August 2017

cites work

1 reference

Anti-integrin monoclonal antibodies

21 January 2018

1 reference

Integrin regulation of lymphocyte trafficking: lessons from structural and signaling studies

21 January 2018

1 reference

Immune cell migration in inflammation: present and future therapeutic targets

21 January 2018

1 reference

alpha4-Integrin antagonism with natalizumab: effects and adverse effects

21 January 2018

1 reference

Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines.

21 January 2018

1 reference

CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1.

21 January 2018

1 reference

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab

21 January 2018

1 reference

Essential roles of VLA-4 in the hematopoietic system

21 January 2018

1 reference

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

21 January 2018

1 reference

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

21 January 2018

1 reference

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

21 January 2018

1 reference

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

21 January 2018

1 reference

Seroepidemiology of human polyomaviruses

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy and newer biological agents

21 January 2018

1 reference

Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study

21 January 2018

1 reference

Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study

21 January 2018

1 reference

Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis

21 January 2018

1 reference

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

Quantitative risk-benefit analysis of natalizumab

21 January 2018

1 reference

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

Detection of JC virus DNA fragments but not proteins in normal brain tissue.

21 January 2018

1 reference

JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Asymptomatic reactivation of JC virus in patients treated with natalizumab

21 January 2018

1 reference

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

21 January 2018

1 reference

Human cytomegalovirus latent infection and associated viral gene expression

21 January 2018

1 reference

Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier

21 January 2018

1 reference

Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation

21 January 2018

1 reference

Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity

21 January 2018

1 reference

The curious incident of the dog in the nighttime: does the absence of virus replication in Epstein-Barr virus-transformed B cells point to an important feature of JC virus biology?

21 January 2018

1 reference

JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab

21 January 2018

1 reference

Monoclonal antibodies and progressive multifocal leukoencephalopathy

21 January 2018

1 reference

PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids

21 January 2018

1 reference

Immune reconstitution inflammatory syndrome and the central nervous system

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after natalizumab monotherapy

21 January 2018

1 reference

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab

21 January 2018

1 reference

Neurological complications of immune reconstitution in HIV-infected populations

21 January 2018

1 reference

Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology

21 January 2018

1 reference

Neurologic consequences of the immune reconstitution inflammatory syndrome (IRIS).

21 January 2018

1 reference

Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis

21 January 2018

1 reference

Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

The Polyomaviridae: Contributions of virus structure to our understanding of virus receptors and infectious entry

21 January 2018

1 reference

Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Determinants of survival in progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2A.

21 January 2018

1 reference

Hexadecyloxypropyl-Cidofovir (CMX001) Suppresses JC Virus Replication in Human Fetal Brain SVG Cell Cultures

21 January 2018

1 reference

CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes

21 January 2018

1 reference

Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.

21 January 2018

1 reference

Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis

21 January 2018

1 reference

Reemergence of PML in natalizumab-treated patients--new cases, same concerns

21 January 2018

1 reference

JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy

21 January 2018

1 reference

Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome

21 January 2018

1 reference

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.

21 January 2018

1 reference

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

Assay design and sample collection can affect anti-John Cunningham virus antibody detection

21 January 2018

1 reference

IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection

21 January 2018

1 reference

Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions

21 January 2018

1 reference

Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis

21 January 2018

1 reference

Younger children with MS have a distinct CSF inflammatory profile at disease onset

21 January 2018

1 reference

Treatment of pediatric multiple sclerosis and variants

21 January 2018

1 reference

Treatment of multiple sclerosis in children and adolescents

21 January 2018

1 reference

Natalizumab in pediatric multiple sclerosis patients

21 January 2018

1 reference

Monoclonal antibodies in MS: mechanisms of action

21 January 2018

1 reference

Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges

21 January 2018

1 reference

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura

21 January 2018

1 reference

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis

21 January 2018

1 reference

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients

21 January 2018

1 reference

Adult murine hematopoiesis can proceed without beta1 and beta7 integrins

21 January 2018

1 reference

Natalizumab effects on immune cell responses in multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECI.11.85

1 reference

26 August 2017

1 reference